How do I know if my Liver Cancer has an actionable mutation

Understanding Actionable Mutations in Liver Cancer

This is an excellent question, and I appreciate you asking it directly. Let me explain what "actionable" means and what the current evidence shows for liver cancer.

What Is an "Actionable" Mutation?

An actionable mutation is a genetic change in your cancer cells that doctors can target with a specific drug or treatment. Think of it like finding the exact lock that a particular key (drug) is designed to open.

The Current Reality for Liver Cancer

Here's what's important to understand based on NCCN Guidelines for Hepatocellular Carcinoma (Version 2.2025):

There is currently NO established indication for routine molecular profiling in liver cancer. This is a critical point: unlike some other cancers where specific mutations directly guide treatment choices, liver cancer doesn't yet have clear "actionable" mutations that change your treatment plan in most cases.

According to the NCCN Guidelines:

"There is no established indication for routine molecular profiling in HCC, but it should be considered on a case-by-case basis. Clinical trials of molecular profiling and/or targeted therapies are encouraged in this population."

What Mutations ARE Found in Liver Cancer?

Hepatocellular carcinomas (HCC) do have various molecular alterations, including:

• Wnt-TGFβ pathway activation
• PI3K-AKT-mTOR pathway activation
• RAS-MAPK pathway activation
• MET pathway activation
• TP53 mutations (common)
• TERT promoter mutations (common)

However, the NCCN Guidelines explicitly state: "To date, however, there are no treatments with differential benefit for specific molecularly defined subgroups of HCC."

This means that even when these mutations are found, they don't necessarily change which treatment your doctor recommends.

When MIGHT Molecular Testing Be Recommended?

According to NCCN Guidelines, molecular testing may be warranted in specific situations:

✅ Atypical histology (unusual appearance under the microscope) ✅ Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) histology ✅ Unusual clinical presentations (your cancer looks or behaves differently than typical) ✅ Clinical trial enrollment (if you're considering participating in a research study)

What About Immunotherapy Biomarkers?

You may have heard about tests for:

• MSI-H/dMMR (microsatellite instability/mismatch repair deficiency)
• TMB-H (tumor mutational burden)
• PD-L1 (immune checkpoint protein)

Important finding: According to NCCN Guidelines, there is no established role for these tests in liver cancer at this time. Immune checkpoint inhibitors (like nivolumab and pembrolizumab) have shown clinical benefit in liver cancer patients without needing to select patients based on these biomarkers.

What Should You Do?

Here are specific questions to ask your oncologist:

1. "Do you recommend molecular profiling for my specific case? Why or why not?"
2. "Are there any clinical trials available that might benefit from my tumor's molecular profile?"
3. "If molecular testing is done, how will the results change my treatment plan?"
4. "What are my treatment options regardless of molecular testing results?"
5. "Are there any emerging biomarkers or tests you're monitoring for my type of liver cancer?"

The Bottom Line

Unlike some cancers where finding a specific mutation opens up targeted therapy options, liver cancer treatment currently focuses more on:

• Tumor stage (how advanced it is)
• Liver function (how well your liver is working)
• Overall health status
• Whether you're eligible for surgery, transplant, or other locoregional therapies

This doesn't mean molecular testing is never useful—it may help identify clinical trial opportunities or provide additional information. But it's not yet a standard decision-making tool for most liver cancer patients.

Your oncologist is best positioned to determine whether molecular profiling makes sense for YOUR specific situation, based on your complete clinical picture.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.